Proactive Investors - Run By Investors For Investors

Emerald Health Therapeutics partners with cannabis researcher VivaCell to boost patent portfolio

The researcher will work with Emerald as it develops medical and recreational cannabis products
Gloved hand holding marijuana in a dish
Emerald Health is a licensed producer authorized by Health Canada to grow, sell and produce cannabis

Cannabis company Emerald Health Therapeutics Inc (CVE:EMH, OTCQX:EMHTF) is looking to strengthen its intellectual property portfolio via a partnership with cannabis-focused research facility VivaCell Biotechnologies.

The institute will work with Emerald Health, evaluating formulas and determining consistent dosages as the company continues to develop medical and recreational cannabis products.

READ: Emerald Health Therapeutics secures long-term supply of hemp for CBD extraction

Emerald Health is a licensed producer authorized by Health Canada to grow, sell and produce cannabis across the country.

“There are a rare few organizations that focus their understanding of the cannabis plant at the heart of its scientific development and strategic operations,” said Emerald CEO Chris Wagner.

The institute partners with academic research centers in Spain like the University of Córdoba, Complutense University of Madrid, Instituto Cajal in Madrid as well as Italy's University of Piemonte Orientale.

The company currently holds 17 patents filed and hopes the data stemming from this partnership will translate into more in the future.

“Our goal is to expand our product pipeline with innovative products substantiated by scientific data and protected by our intellectual property,” added Wagner.

VivaCell is a wholly-owned subsidiary of Emerald Health Sciences, which has a 32% stake in Emerald Health Therapeutics Inc.

Shares of Emerald Health were up slightly to $3.89 by the closing bell Tuesday.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full EMH profile View Profile

Emerald Health Therapeutics Inc Timeline

Related Articles

tablets and pills
Tue
Here we take a closer look at Clinigen, the specialty pharma group and AIM billionaire
A doctor's stethoscope and a marijuana plant
February 22 2019
With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals
seeds in a bowl
March 07 2019
The Vancouver company is developing Omega-3 products as oil, powder or emulsion to be used as food additives
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use